CN113730525A

CN113730525A - Traditional Chinese medicine composition for treating postmenopausal osteoporosis and application thereof

Info

Publication number: CN113730525A
Application number: CN202111233719.6A
Authority: CN
Inventors: 詹炜祎; 刘光明; 孙波; 杨佳裕; 季伟; 邵铮; 蒋恩宇; 钱晋宇
Original assignee: Shanghai Huangpu District Xiangshan Hospital Of Traditional Chinese Medicine
Current assignee: Shanghai Huangpu District Xiangshan Hospital Of Traditional Chinese Medicine
Priority date: 2021-10-22
Filing date: 2021-10-22
Publication date: 2021-12-03

Abstract

The invention relates to the technical field of traditional Chinese medicines, in particular to a traditional Chinese medicine composition for treating postmenopausal osteoporosis and application thereof, wherein the traditional Chinese medicine composition is prepared from the following raw material medicines in parts by weight: 40 parts of epimedium, 40 parts of morinda officinalis, 60 parts of fructus psoraleae, 60 parts of fructus alpiniae oxyphyllae, 60 parts of salvia miltiorrhiza, 60 parts of angelica sinensis, 60 parts of radix clematidis, 6-8 parts of human placenta, 6-8 parts of tortoise-shell glue, 60 parts of rhizoma anemarrhenae and 60 parts of rhizoma cibotii. The invention also comprises application of the traditional Chinese medicine composition in preparing a medicine for treating postmenopausal osteoporosis. Its advantages are: aiming at the pathogenesis of postmenopausal osteoporosis, the raw material medicines and the weight part ratio of the raw material medicines are preferably selected, and the raw material medicines have synergistic effect, so that the traditional Chinese medicine has obvious curative effect on osteoporosis with liver and kidney deficiency.

Description

Traditional Chinese medicine composition for treating postmenopausal osteoporosis and application thereof

Technical Field

The invention relates to the technical field of traditional Chinese medicines, in particular to a traditional Chinese medicine composition for treating postmenopausal osteoporosis and application thereof.

Background

Osteoporosis is a systemic metabolic bone disease in which bone mass is reduced, bone microstructure is degraded, bone fragility is increased, and pathological fracture is liable to occur. The disease can be divided into primary and secondary types due to different causes. Primary osteoporosis is more common in clinic and mainly appears as postmenopausal osteoporosis, senile osteoporosis and idiopathic osteoporosis of women. It is characterized by a decrease in bone density and a deterioration in the bone's microstructure, leading to an increased risk of fracture. Osteoporotic fractures are the most serious consequence of senile osteoporosis. With the prolongation of life expectancy and the change of population structure, especially the aggravation of the aging condition of the society, people suffering from osteoporosis show a trend of rising year by year, and the incidence of people with the age of more than 60 years is sharply increased, and women are more than men in general. Pain and increased fracture risk caused by osteoporosis have seriously threatened the quality of life of the elderly. Therefore, osteoporosis prevention, diagnosis and treatment are currently critical targets.

Postmenopausal osteoporosis (PMO) is a common disease related to aging, mainly occurs in postmenopausal women, due to the fact that estrogen is deficient, the bone mass is reduced, the bone tissue structure is changed, the bone fragility is increased, the bone fracture is easy, pain, bone deformation, complications and the like caused by the bone fracture seriously affect the health and the life quality of old people, and even the life is shortened. Postmenopausal women have a 4-fold higher prevalence of PMO than men. WHO is defined for osteoporosis as a bone density below normal by more than 2.5 standard deviations under dual energy X-ray (DEXA). The lack of estrogen is one of the major causes of PMO, and estrogen promotes early osteoblast differentiation, stimulates collagen and inhibits osteoclast activity. After menopause, the estrogen is seriously insufficient, so that the activity of osteoclast is increased, the bone density is reduced, the bone transformation rate is increased, the calcium salt deposition is influenced, the bone digestion is increased, a large amount of bone is lost, and finally PMO is caused. PMOs can be divided into two categories: firstly, the postmenopausal osteoporosis in early stage is characterized by rapid loss of bone mass and is related to the decline of estrogen after menopause; ② the postmenopausal osteoporosis in the later period, which occurs 10-20 years after menopause, the bone mass loss is slow, and the secondary hyperparathyroidism of the old causes the PMO to be further worsened. The clinical manifestations are as follows:

1. bone pain: osteoporosis is usually caused by microfracture of the trabecular bone, and when the posture changes, muscle and ligament are pulled, so that sitting pain, anterior flexion and posterior extension pain, walking pain, turning over pain, lying pain and the like can occur.

2. Humpback or short stature: this occurs when the spine is fractured compressively.

3. Local tenderness or tapping pain: it features no local inflammation and fever.

However, there are many methods and medicines for treating postmenopausal osteoporosis, but the problem groups find that the curative effect of the medicines or methods on the market is not ideal. In consideration of the above, the subject group distinguishes the entire disease by combining the traditional Chinese medicine on the basis of inheriting and applying the academic thought of maintenance intelligence injury, focuses on tonifying the first and the last days in treatment, mostly uses the method of tonifying the kidney and the spleen, combines the pathogenesis characteristics of osteoporosis, namely deficiency and stasis, realizes treatment by distinguishing the symptoms and signs, corrects imbalance yin and yang, achieves new balance, and plays a role in preventing and treating osteoporosis.

The Chinese patent application: CN201910083733.9 discloses a Chinese medicinal composition. The traditional Chinese medicine composition has the effects of tonifying kidney, replenishing essence, strengthening bones and generating marrow, can regulate the decline of the function of generating marrow of climacteric women caused by kidney qi deficiency and qi and blood deficiency, and can prevent and treat osteoporosis. A traditional Chinese medicine composition for treating postmenopausal osteoporosis is prepared from the following effective pharmaceutical ingredients in parts by weight: 0.75-3 parts of prepared rehmannia root, 0.41-0.84 part of dodder, 0.75-2.25 parts of achyranthes root, 6-9 parts of tortoise-plastron glue, 6-9 parts of deerhorn glue, 0.6-1.2 parts of Chinese yam, 0.3-1.5 parts of dogwood, 1.81-4.55 parts of medlar, 0.3-0.75 part of epimedium herb and 0.3-1.5 parts of glossy privet fruit.

The Chinese patent application: 201510959592.4A Chinese medicinal composition for treating female postmenopausal osteoporosis and its preparation method are disclosed. The traditional Chinese medicine composition comprises the following preparation raw materials in parts by weight: 5-25 parts of folium artemisiae argyi, 6-25 parts of astragalus membranaceus, 9-30 parts of codonopsis pilosula, 9-15 parts of rhizoma polygonati, 6-15 parts of ligusticum wallichii, 9-15 parts of prepared rehmannia root, 3-9 parts of rhizoma drynariae, 3-9 parts of radix clematidis, 3-9 parts of radix angelicae, 6-12 parts of dogwood, 3-9 parts of radix cyathulae and 1-10 parts of liquorice. The traditional Chinese medicine composition has the advantages of small toxic and side effects, liver and kidney benefiting, blood circulation activating, pain relieving, muscle and bone strengthening and strengthening effects, and can effectively treat female postmenopausal osteoporosis.

However, the inventor finds that the clinical curative effect of the components is not ideal. Therefore, the subject group provides a new traditional Chinese medicine formula for treating postmenopausal osteoporosis, and the traditional Chinese medicine composition for treating postmenopausal osteoporosis and the application thereof are not reported at present.

Disclosure of Invention

The invention aims to provide a traditional Chinese medicine composition for treating postmenopausal osteoporosis and application thereof, aiming at the defects of the prior art.

In order to achieve the purpose, the invention adopts the technical scheme that:

in a first aspect, the invention provides a traditional Chinese medicine composition for treating postmenopausal osteoporosis, which comprises the following raw material medicines in parts by weight: 30-40 parts of epimedium, 30-40 parts of morinda officinalis, 50-60 parts of fructus psoraleae, 50-60 parts of fructus alpiniae oxyphyllae, 50-60 parts of salvia miltiorrhiza, 50-60 parts of angelica sinensis, 50-60 parts of radix clematidis, 6-8 parts of human placenta, 6-8 parts of tortoise-shell glue, 50-60 parts of rhizoma anemarrhenae and 50-60 parts of rhizoma cibotii.

Preferably, the traditional Chinese medicine composition consists of the following raw material medicines in parts by weight: 35-40 parts of epimedium, 35-40 parts of morinda officinalis, 55-60 parts of fructus psoraleae, 55-60 parts of fructus alpiniae oxyphyllae, 55-60 parts of salvia miltiorrhiza, 55-60 parts of angelica sinensis, 55-60 parts of radix clematidis, 7-8 parts of human placenta, 7-8 parts of tortoise-shell glue, 55-60 parts of rhizoma anemarrhenae and 55-60 parts of rhizoma cibotii.

Preferably, the traditional Chinese medicine composition consists of the following raw material medicines in parts by weight: 40 parts of epimedium, 40 parts of morinda officinalis, 60 parts of fructus psoraleae, 60 parts of fructus alpiniae oxyphyllae, 60 parts of salvia miltiorrhiza, 60 parts of angelica sinensis, 60 parts of radix clematidis, 8 parts of human placenta, 8 parts of tortoise-shell glue, 60 parts of rhizoma anemarrhenae and 60 parts of rhizoma cibotii.

Preferably, the traditional Chinese medicine composition further comprises a pharmaceutically acceptable carrier.

Preferably, the Chinese medicinal composition is in the form of decoction, pills, tablets, mixture, capsules, granules, powder or paste.

In a second aspect, the present invention provides a preparation method of the above-mentioned traditional Chinese medicine composition, comprising the step of weighing the raw materials according to the weight part ratio.

In a third aspect, the invention provides an application of the traditional Chinese medicine composition in preparing a medicine for treating postmenopausal osteoporosis.

Further, the invention provides application of the traditional Chinese medicine composition in preparing a medicine for treating kidney-yang deficiency type postmenopausal osteoporosis.

Further, the invention provides application of the traditional Chinese medicine composition in preparing a medicine for treating liver-kidney yin deficiency type postmenopausal osteoporosis.

Square solution

The department of traumatology of Schneider combines the research result of modern medicine, under the guidance of the theory of traditional Chinese medicine, through many years of clinical practice, have formed a set of effective methods of clinical tradition to the treatment of osteoporosis. The Schneider considers that kidney governs bone because kidney governs storing essence, while essence can produce marrow, which is in bone, and bone depends on marrow to nourish. While kidney essence is divided into kidney yin and kidney yang, which plays a role in nourishing and moistening; kidney yang plays a role in promoting and warming. The two are mutually restricted, interdependent and interdependent, maintaining the relative balance of yin and yang of the body. When kidney essence is deficient to a certain extent, bone metabolism is disturbed, resulting in osteoporosis. Therefore, tonifying the kidney becomes the key point of the traditional Chinese medicine for treating osteoporosis, the department of traumatology of Schlempe puts forward the theory of a kidney warming and yin nourishing method according to years of clinical experience summary, more than ten traditional Chinese medicines with the effects of strengthening bones and muscles, warming kidney and nourishing yin, and promoting blood circulation and removing meridian obstruction are selected, and the home-made preparation for treating primary osteoporosis, namely the Guiguizhuanggu tablet, is created. The formula uses rhizoma cibotii to tonify kidney qi and strengthen muscles and bones; fructus Psoraleae can strengthen body constitution and promote bone growth; morinda officinalis and Epimedium herb strengthen yang and strengthen kidney; human placenta and tortoise-shell glue as essence and blood tonics can nourish yin and fill essence and blood, and are combined with Zhi mu for purging lung and nourishing kidney, Dan Shen and Dang Gui for activating blood and unblocking meridians to alleviate pain. The earlier research also proves that the Guigui Zhuanggu tablets have remarkable curative effect on osteoporosis caused by liver and kidney deficiency.

Clinically, people find that postmenopausal women have increasingly osteoporosis, while the chief complaint is waist and back pain, and the Guigui bone strengthening tablet applied to the postmenopausal osteoporosis also has a good treatment effect on the waist and back pain. The onset of postmenopausal osteoporosis is considered to be closely related to essence and qi deficiency of kidney, and after women suffer from exhaustion, the balance between kidney yin and kidney yang is destroyed, so that essence and qi are lost, essence cannot generate marrow, and bones are lost of nourishment. Therefore, kidney essence deficiency is the main pathogenesis of postmenopausal osteoporosis, low back pain is one of the primary clinical manifestations in the early stage, and the treatment principle of warming and invigorating kidney yang, nourishing kidney yin and tonifying yin and yang should be emphasized in treatment, which is contrary to the theory of 'warming kidney and nourishing yin' of the family I. Therefore, we propose the hypothesis that if Guigui Zhuanggu tablets can improve and treat postmenopausal osteoporotic lumbago? Furthermore, relevant experimental researches prove that the prescription prepared according to the proportion has unexpected technical effects in curative effect.

Term(s) for

As used herein, the term "pharmaceutically acceptable carrier" refers to a carrier for administration of a therapeutic agent, including various excipients and diluents and the like. The term refers to such pharmaceutical carriers: they are not essential active ingredients per se and are not unduly toxic after administration. Suitable carriers are well known to those of ordinary skill in the art.

As used herein, "parts by weight" can be any fixed weight expressed in milligrams, grams, or kilograms (e.g., 1mg, 1g, 2g, 5g, or 1kg, etc.). For example, a composition consisting of 1 part by weight of component a and 9 parts by weight of component b may be a composition consisting of 1g of component a +9 g of component b, or 10 g of component a +90 g of component b. In the composition, the percentage content of a certain component is (parts by weight of the component/sum of parts by weight of all components) × 100%. Thus, in a composition consisting of 1 part by weight of component a and 9 parts by weight of component b, the content of component a is 10% and component b is 90%.

Dosage forms

The dosage form of the Chinese medicinal composition of the present invention is not particularly limited, and may be any dosage form suitable for administration to mammals.

The invention has the advantages that:

1. the traditional Chinese medicine composition is obtained by further optimizing the weight part ratio of the medicines on the basis of the prior proved formula, the whole formula takes a kidney warming and yin nourishing method as a treatment principle, and the rhizoma cibotii is used for tonifying kidney qi and strengthening bones and muscles in the formula; fructus Psoraleae can strengthen body constitution and promote bone growth; morinda officinalis and Epimedium herb strengthen yang and strengthen kidney; human placenta and tortoise-shell glue as essence and blood tonics can nourish yin and fill essence and blood, and are combined with Zhi mu for purging lung and nourishing kidney, Dan Shen and Dang Gui for activating blood and unblocking meridians to alleviate pain. Compared with the formula in the early-stage weight ratio, the formula in the prior art is adjusted in weight ratio, and animal experiment results show that the curative effect of the adjusted formula is obviously superior to that of the prior formula and the formula in other weight ratios.

2. The traditional Chinese medicine composition can be prepared into different formulations according to the needs of patients, so that the trouble of self-decoction of the medicines of the patients is avoided, and the traditional Chinese medicine composition has no obvious adverse reaction and complication, and is safe and reliable.

Detailed Description

The invention will be further illustrated with reference to specific embodiments. It should be understood that these examples are for illustrative purposes only and are not intended to limit the scope of the present invention. Furthermore, it should be understood that various changes and modifications can be made by those skilled in the art after reading the disclosure of the present invention, and equivalents fall within the scope of the appended claims.

EXAMPLE 1 Chinese medicinal composition 1

30 parts of epimedium, 30 parts of morinda officinalis, 50 parts of fructus psoraleae, 50 parts of fructus alpiniae oxyphyllae, 50 parts of salvia miltiorrhiza, 50 parts of angelica sinensis, 50 parts of radix clematidis, 6 parts of human placenta, 6 parts of tortoise-shell glue, 50 parts of rhizoma anemarrhenae and 50 parts of rhizoma cibotii.

EXAMPLE 2 Chinese medicinal composition (II)

40 parts of epimedium, 40 parts of morinda officinalis, 60 parts of fructus psoraleae, 60 parts of fructus alpiniae oxyphyllae, 60 parts of salvia miltiorrhiza, 60 parts of angelica sinensis, 60 parts of radix clematidis, 8 parts of human placenta, 8 parts of tortoise-shell glue, 60 parts of rhizoma anemarrhenae and 60 parts of rhizoma cibotii.

EXAMPLE 3 Chinese medicinal composition (III)

30 parts of epimedium, 40 parts of morinda officinalis, 50 parts of fructus psoraleae, 60 parts of fructus alpiniae oxyphyllae, 50 parts of salvia miltiorrhiza, 60 parts of angelica sinensis, 50 parts of radix clematidis, 8 parts of human placenta, 6 parts of tortoise-shell glue, 60 parts of rhizoma anemarrhenae and 50 parts of rhizoma cibotii.

EXAMPLE 4 Chinese medicinal composition (IV)

40 parts of epimedium, 30 parts of morinda officinalis, 60 parts of fructus psoraleae, 50 parts of fructus alpiniae oxyphyllae, 60 parts of salvia miltiorrhiza, 50 parts of angelica sinensis, 60 parts of radix clematidis, 6 parts of human placenta, 8 parts of tortoise-shell glue, 50 parts of rhizoma anemarrhenae and 60 parts of rhizoma cibotii.

EXAMPLE 5 Chinese medicinal composition (V)

35 parts of epimedium, 35 parts of morinda officinalis, 55 parts of fructus psoraleae, 55 parts of fructus alpiniae oxyphyllae, 55 parts of salvia miltiorrhiza, 55 parts of angelica, 55 parts of radix clematidis, 7 parts of human placenta, 7 parts of tortoise-shell glue, 55 parts of rhizoma anemarrhenae and 55 parts of rhizoma cibotii.

EXAMPLE 6 Chinese medicinal composition (VI)

35 parts of epimedium, 40 parts of morinda officinalis, 55 parts of fructus psoraleae, 60 parts of fructus alpiniae oxyphyllae, 55 parts of salvia miltiorrhiza, 60 parts of angelica sinensis, 55 parts of radix clematidis, 8 parts of human placenta, 7 parts of tortoise-shell glue, 60 parts of rhizoma anemarrhenae and 55 parts of rhizoma cibotii.

EXAMPLE 7 Chinese medicinal composition (seven)

40 parts of epimedium, 35 parts of morinda officinalis, 60 parts of fructus psoraleae, 55 parts of fructus alpiniae oxyphyllae, 60 parts of salvia miltiorrhiza, 55 parts of angelica, 60 parts of radix clematidis, 7 parts of human placenta, 8 parts of tortoise-shell glue, 55 parts of rhizoma anemarrhenae and 60 parts of rhizoma cibotii.

Example 8 decoction

The preparation method comprises the following steps:

the raw materials are taken according to the weight parts of the raw materials in the embodiments 1-7 respectively, cleaned and decocted in water for 2 times, and each time lasts for 1 hour.

Example 8 granules

The preparation method comprises the following steps:

the preparation method comprises the following steps of taking the raw materials according to the weight part ratio of the embodiments 1-7, cleaning the raw materials, adding water, decocting for 2 times, 1 hour each time, filtering, combining the filtrates, concentrating, cooling, adding granule adjuvants, and making into granules according to a conventional method.

Example 9 tablets/capsules

The preparation method comprises the following steps:

the raw materials are respectively taken according to the weight part ratio of the embodiments 1-7, cleaned and decocted for 2 times by adding water, 1 hour each time, filtered, the filtrates are combined, concentrated and cooled, pharmaceutical auxiliary materials are added, vacuum drying is carried out, crushing and granulating are carried out, and tablets or filled and encapsulated are prepared by pressing. The whole preparation process only needs to be decocted once.

EXAMPLE 10 pellets

The preparation method comprises the following steps:

the raw materials are respectively taken according to the weight part ratio of the embodiments 1-7, ground into fine powder, sieved by a 80-mesh sieve for later use, and prepared according to the conventional pill preparation method.

Example 11 animal experiments

1 Experimental animal and molding method

60 Wistar female rats with the age of three months are randomly divided into 6 groups, namely a blank group, a pseudo-operation group, a model group, an experimental group, a control group and a control group, wherein each group comprises 10 rats, and except the blank group, the rest groups model the rats according to the ovariectomized postmenopausal osteoporosis model (the pseudo-operation group is operated according to the same operation method, but ovaries on two sides are not removed).

The molding method comprises the following steps: rats were anesthetized by intramuscular injection for sterile surgery to remove both ovaries, and then the wounds were sutured. In which the sham group did not remove the ovaries.

2 method of administration

After the molding is finished, the blank group, the sham operation group and the model group are filled with the normal saline.

Experimental group gavage of a solution of a Chinese medicinal composition 3 times a day, 2ml each time (0.1 g/ml): 40 parts of epimedium, 40 parts of morinda officinalis, 60 parts of fructus psoraleae, 60 parts of fructus alpiniae oxyphyllae, 60 parts of salvia miltiorrhiza, 60 parts of angelica sinensis, 60 parts of radix clematidis, 8 parts of human placenta, 8 parts of tortoise-shell glue, 60 parts of rhizoma anemarrhenae and 60 parts of rhizoma cibotii.

The control group of gavage traditional Chinese medicine composition solution is taken 3 times a day, and 2ml (0.1g/ml) is taken for each time: 20 parts of epimedium, 25 parts of morinda officinalis, 65 parts of fructus psoraleae, 62 parts of fructus alpiniae oxyphyllae, 61 parts of salvia miltiorrhiza, 61 parts of angelica sinensis, 45 parts of radix clematidis, 5 parts of human placenta, 5 parts of tortoise-shell glue, 45 parts of rhizoma anemarrhenae and 45 parts of rhizoma cibotii.

The two groups of control gastric lavage traditional Chinese medicine composition solutions are taken 3 times a day, and 2ml (0.1g/ml) is taken for each time: 35 parts of epimedium, 27 parts of morinda officinalis, 48 parts of fructus psoraleae, 63 parts of fructus alpiniae oxyphyllae, 48 parts of salvia miltiorrhiza, 45 parts of angelica, 45 parts of radix clematidis, 7 parts of human placenta, 5 parts of tortoise-shell glue, 61 parts of rhizoma anemarrhenae and 61 parts of rhizoma cibotii.

The rats in each group were dosed continuously for 3 months.

3 observation index

The drinking water, activity, mental state and the like of the rats in each group during the medication period are observed.

After the administration, the rats were sacrificed under excessive anesthesia, and the results of bone density and osteoprotegerin of the right hind limb femur of each group of rats were determined.

4 statistical method

Calculated in excel2010, expressed as mean ± standard deviation.

5 results

During the administration period, the model group has loose hair, listlessness, slow response and anorexia, the sham operation group is similar to the blank group, the model group shows normal spirit, no rat symptoms exist in the model group, and the experimental group, the control group and the control group show symptoms between the model group and the normal group.

Bone density (g/cm) of thighbone of rats in each group²) The raw data are respectively:

blank group: 0.18, 0.17, 0.19, 0.18, 0.19, 0.18, 0.17;

the sham operation group: 0.17, 0.18, 0.17, 0.18;

model group: 0.16, 0.17, 0.16, 0.15, 0.16;

experimental groups: 0.17, 0.18, 0.17, 0.18, 0.17;

control group: 0.16, 016, 0.17, 0.15, 0.16, 0.17, 0.16, 0.17;

control two groups: 0.16, 0.17, 0.16, 0.15, 0.17, 0.16, 0.17, 0.16;

the results of bone density of femurs of the rats in each group are shown in table 1.

Table 1 femoral bone Density results for various groups of rats

Group of	n	Femoral BMD (g/cm)²)
			Blank group	10	0.180±0.008
Artificial operation group	10	0.175±0.005
			Model set	10	0.160±0.007
Experimental group	10	0.174±0.005
			Control group	10	0.162±0.006
Control two groups	10	0.164±0.007

The initial data of Osteoprotegerin (OPG) after administration to rats in each group are:

blank group: 3478. 3470, 3477, 3485, 3488, 3489, 3488, 3482, 3470, 3477;

the sham operation group: 3442. 3455, 3453, 3442, 3445, 3436, 3442, 3443;

model group: 1732. 1720, 1723, 1734, 1744, 1750, 1773, 1740, 1754, 1745;

experimental groups: 3004. 3003, 3010, 3016, 3010, 2998, 2990, 2987, 2997, 2998;

control group: 2643. 2656, 2645, 2646, 2655, 2663, 2664, 2656, 2670, 2663;

control two groups: 2688. 2670, 2665, 2676, 2687, 2680, 2686, 2674, 2690, 2699;

the results of rat Osteoprotegerin (OPG) for each group are shown in Table 2.

TABLE 2 rat Osteoprotegerin (OPG) results for each group

Group of	n	OPG(ng/L)
			Blank group	10	3480.4±7.14
Artificial operation group	10	3443.9±6.19
			Model set	10	1741.5±15.61
Experimental group	10	3001.3±9.13
			Control group	10	2656.1±9.12
Control two groups	10	2681.5±10.35

As can be seen from the data in tables 1-2, the femur density and osteoprotegerin of the model group are significantly reduced compared to the blank group and the sham operation group, indicating that the model was successfully fabricated, while the experimental group is significantly improved compared to the control group and the control group, indicating that the formula of the experimental group has unexpected technical effects compared to the control group and the control group, indicating that the curative effects of the traditional Chinese medicine formula in the weight ratio of the present invention are significantly improved.

The foregoing is only a preferred embodiment of the present invention, and it should be noted that, for those skilled in the art, various modifications and additions can be made without departing from the principle of the present invention, and these should also be considered as the protection scope of the present invention.

Claims

1. The traditional Chinese medicine composition for treating postmenopausal osteoporosis is characterized by comprising the following raw material medicines in parts by weight: 30-40 parts of epimedium, 30-40 parts of morinda officinalis, 50-60 parts of fructus psoraleae, 50-60 parts of fructus alpiniae oxyphyllae, 50-60 parts of salvia miltiorrhiza, 50-60 parts of angelica sinensis, 50-60 parts of radix clematidis, 6-8 parts of human placenta, 6-8 parts of tortoise-shell glue, 50-60 parts of rhizoma anemarrhenae and 50-60 parts of rhizoma cibotii.

2. The traditional Chinese medicine composition according to claim 1, which is prepared from the following raw materials in parts by weight: 35-40 parts of epimedium, 35-40 parts of morinda officinalis, 55-60 parts of fructus psoraleae, 55-60 parts of fructus alpiniae oxyphyllae, 55-60 parts of salvia miltiorrhiza, 55-60 parts of angelica sinensis, 55-60 parts of radix clematidis, 7-8 parts of human placenta, 7-8 parts of tortoise-shell glue, 55-60 parts of rhizoma anemarrhenae and 55-60 parts of rhizoma cibotii.

3. The traditional Chinese medicine composition according to claim 1, which is prepared from the following raw materials in parts by weight: 40 parts of epimedium, 40 parts of morinda officinalis, 60 parts of fructus psoraleae, 60 parts of fructus alpiniae oxyphyllae, 60 parts of salvia miltiorrhiza, 60 parts of angelica sinensis, 60 parts of radix clematidis, 8 parts of human placenta, 8 parts of tortoise-shell glue, 60 parts of rhizoma anemarrhenae and 60 parts of rhizoma cibotii.

4. The Chinese medicinal composition of any one of claims 1-3, wherein the Chinese medicinal composition further comprises a pharmaceutically acceptable carrier.

5. The Chinese medicinal composition according to any one of claims 1 to 3, wherein the Chinese medicinal composition is in the form of decoction, pill, tablet, mixture, capsule, granule, powder or paste.

6. The preparation method of the traditional Chinese medicine composition as claimed in any one of claims 1 to 5, which is characterized by comprising the step of weighing the raw materials according to the weight part ratio.

7. Use of a Chinese medicinal composition according to any one of claims 1 to 5 in the manufacture of a medicament for the treatment of postmenopausal osteoporosis.

8. The use of the Chinese medicinal composition of any one of claims 1-5 in the preparation of a medicament for the treatment of kidney-yang deficiency type postmenopausal osteoporosis.

9. The use of the Chinese medicinal composition of any one of claims 1-5 in the preparation of a medicament for treating liver-kidney yin deficiency type postmenopausal osteoporosis.